BCRX

Biocryst Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality8/10
  • Growth↑ 8/10
  • Momentum↓ 3/10
Biocryst Pharmaceuticals sales and earnings growth
BCRX Growth
Good
  • Revenue Y/Y↑ 45.38%
  • EPS Y/Y↑ 91.80%
  • FCF Y/Y↑ 184.36%
Biocryst Pharmaceuticals gross and profit margin trends
BCRX Profitability
Great
  • Gross margin ↑ 97.40%
  • EPS margin↓ -1.50%
  • ROIC↓ 8.40%
Biocryst Pharmaceuticals net debt vs free cash flow
BCRX Risk
Great
  • Debt / Equity↓ -1.8
  • Debt / FCF↑ 12.5
  • Interest coverage↓ 0.9

Biocryst Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗